Ebdarokimab Biosimilar – Anti-IL12B mAb – Research Grade

Introduction to Ebdarokimab Biosimilar – Anti-IL12B mAb – Research Grade

Ebdarokimab Biosimilar, also known as Anti-IL12B monoclonal antibody (mAb), is a promising therapeutic agent that is currently being developed as a biosimilar to the original Ebdarokimab. This biosimilar is a potent inhibitor of interleukin-12 (IL-12), a cytokine that plays a crucial role in the regulation of immune responses. In this article, we will explore the structure, activity, and potential applications of Ebdarokimab Biosimilar in research.

Structure of Ebdarokimab Biosimilar – Anti-IL12B mAb – Research Grade

Ebdarokimab Biosimilar is a recombinant humanized monoclonal antibody that is composed of two heavy chains and two light chains. The heavy chains are made up of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains contain one constant domain (CL) and one variable domain (VL). The variable domains of both the heavy and light chains are responsible for the binding of Ebdarokimab Biosimilar to its target, IL-12.

Mechanism of Action of Ebdarokimab Biosimilar – Anti-IL12B mAb – Research Grade Ebdarokimab Biosimilar exerts its therapeutic effects by binding to the p40 subunit of IL-12, thereby preventing its interaction with the IL-12 receptor. This results in the inhibition of IL-12 signaling, which is essential for the activation and proliferation of T cells and natural killer cells. By blocking IL-12, Ebdarokimab Biosimilar helps to regulate the immune response and reduce inflammation.

Title: Potential Applications of Ebdarokimab Biosimilar – Anti-IL12B mAb – Research Grade Ebdarokimab Biosimilar has shown promising results in pre-clinical studies and is currently being evaluated for its potential use in various inflammatory and autoimmune diseases. Some of the diseases that could potentially benefit from Ebdarokimab Biosimilar include psoriasis, Crohn’s disease, rheumatoid arthritis, and multiple sclerosis. Additionally, this biosimilar could also be used in the treatment of certain types of cancer, as IL-12 has been shown to have anti-tumor effects.

Advantages of Ebdarokimab Biosimilar – Anti-IL12B mAb – Research Grade

One of the main advantages of Ebdarokimab Biosimilar is its similarity to the original Ebdarokimab, which has been extensively studied and has a proven safety and efficacy profile. This biosimilar also offers a lower cost alternative to the original drug, making it more accessible to patients. Furthermore, Ebdarokimab Biosimilar is produced using recombinant DNA technology, ensuring consistency and quality in every batch.

Title: Research Grade Ebdarokimab Biosimilar – Anti-IL12B mAb for Scientific Studies Ebdarokimab Biosimilar is currently being developed as a research-grade product, making it an ideal tool for scientific studies. Its high specificity and potency make it a valuable tool for investigating the role of IL-12 in various disease models. Additionally, the availability of a research-grade biosimilar allows for more cost-effective and efficient research, as compared to using the original drug.

Conclusion

In conclusion, Ebdarokimab Biosimilar – Anti-IL12B mAb – Research Grade is a promising therapeutic agent that has the potential to be used in the treatment of various inflammatory and autoimmune diseases. Its structure, mechanism of action, and potential applications make it a valuable tool for scientific research. With further development and clinical trials, Ebdarokimab Biosimilar could potentially offer a more affordable and accessible treatment option for patients in need.

ProteoGenix catalogue number PX-TA1660. For research use only.

Target: Ebdarokimab Biosimilar – Anti-IL12B mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet